Skip to main content

Market Overview

Why Regeneron's Stock Is Trading Higher Today

Share:
Why Regeneron's Stock Is Trading Higher Today

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher on Tuesday after the company announced it has been awarded a $450 million contract to manufacture and supply REGN-COV2 Anti-Viral Antibody Cocktail.

Regeneron discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis.

Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Regeneron shares are trading up 3.69% at $650.40 at time of publication on Tuesday. The stock has a 52-week high of $651.31 and a 52-week low of $271.37.

 

Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com